Nantong Jiangshan Agrochemical & Chemicals Co.,Ltd. (SHA:600389)
25.43
+0.46 (1.84%)
Feb 6, 2026, 2:14 PM CST
SHA:600389 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,597 | 5,374 | 5,034 | 8,252 | 5,507 | 4,342 |
Other Revenue | 57.31 | 57.31 | 51.99 | 96.58 | 977.15 | 779.39 |
| 5,655 | 5,432 | 5,086 | 8,349 | 6,484 | 5,121 | |
Revenue Growth (YoY) | -2.10% | 6.80% | -39.09% | 28.76% | 26.60% | 7.12% |
Cost of Revenue | 4,678 | 4,678 | 4,449 | 5,724 | 5,052 | 4,372 |
Gross Profit | 977.09 | 753.1 | 637.11 | 2,625 | 1,432 | 749.51 |
Selling, General & Admin | 277.67 | 311.91 | 273.81 | 271.13 | 213.61 | 152.67 |
Research & Development | 202.97 | 207.01 | 149.11 | 255.92 | 237.3 | 169.38 |
Other Operating Expenses | 30.17 | 16.98 | 2.28 | 23.82 | 15 | 13.85 |
Operating Expenses | 517.43 | 540.38 | 388.56 | 550.88 | 463.86 | 352.74 |
Operating Income | 459.67 | 212.72 | 248.55 | 2,074 | 968.28 | 396.77 |
Interest Expense | -25.44 | -22.05 | -22.75 | -25.36 | -22.31 | -29.43 |
Interest & Investment Income | 168.34 | 112.74 | 102.2 | 41.12 | 55.41 | 56.67 |
Currency Exchange Gain (Loss) | 15.85 | 15.85 | 6.04 | 114.11 | -13.6 | -24.55 |
Other Non Operating Income (Expenses) | 2.96 | 4.01 | -3.45 | -1.79 | -1.18 | -1.71 |
EBT Excluding Unusual Items | 621.37 | 323.26 | 330.59 | 2,202 | 986.6 | 397.75 |
Impairment of Goodwill | -1.67 | -1.67 | - | - | - | - |
Gain (Loss) on Sale of Investments | -1.11 | 0.18 | 2.82 | -14.74 | 12.11 | -2.89 |
Gain (Loss) on Sale of Assets | -26.48 | -18.49 | -8.98 | 16.02 | -26.94 | -15.36 |
Asset Writedown | 5.4 | - | - | - | - | - |
Other Unusual Items | 27.42 | 12.44 | 16.54 | 4.09 | 13.04 | 9.32 |
Pretax Income | 624.92 | 315.73 | 340.96 | 2,207 | 984.81 | 388.82 |
Income Tax Expense | 149.91 | 87.95 | 56.61 | 343.8 | 157.96 | 44.88 |
Earnings From Continuing Operations | 475.01 | 227.78 | 284.35 | 1,864 | 826.85 | 343.94 |
Minority Interest in Earnings | 3.07 | -3.38 | -1.39 | -19.2 | -10.4 | -9.01 |
Net Income | 478.08 | 224.4 | 282.95 | 1,844 | 816.45 | 334.93 |
Net Income to Common | 478.08 | 224.4 | 282.95 | 1,844 | 816.45 | 334.93 |
Net Income Growth | 141.55% | -20.69% | -84.66% | 125.91% | 143.77% | 11.62% |
Shares Outstanding (Basic) | 432 | 432 | 435 | 437 | 431 | 431 |
Shares Outstanding (Diluted) | 432 | 432 | 435 | 437 | 431 | 431 |
Shares Change (YoY) | -0.43% | -0.87% | -0.29% | 1.38% | -0.01% | 0.01% |
EPS (Basic) | 1.11 | 0.52 | 0.65 | 4.22 | 1.90 | 0.78 |
EPS (Diluted) | 1.11 | 0.52 | 0.65 | 4.22 | 1.90 | 0.78 |
EPS Growth | 142.58% | -20.00% | -84.61% | 122.83% | 143.78% | 11.61% |
Free Cash Flow | -889.42 | -908.22 | 315.03 | 1,584 | 821.93 | 508.03 |
Free Cash Flow Per Share | -2.06 | -2.10 | 0.72 | 3.63 | 1.91 | 1.18 |
Dividend Per Share | 0.550 | 0.300 | - | 2.207 | 1.379 | 1.034 |
Dividend Growth | 175.00% | - | - | 60.00% | 33.33% | 383.86% |
Gross Margin | 17.28% | 13.87% | 12.53% | 31.44% | 22.09% | 14.64% |
Operating Margin | 8.13% | 3.92% | 4.89% | 24.84% | 14.93% | 7.75% |
Profit Margin | 8.46% | 4.13% | 5.56% | 22.09% | 12.59% | 6.54% |
Free Cash Flow Margin | -15.73% | -16.72% | 6.19% | 18.98% | 12.68% | 9.92% |
EBITDA | 662.89 | 431.02 | 486.95 | 2,313 | 1,188 | 598.26 |
EBITDA Margin | 11.72% | 7.94% | 9.57% | 27.71% | 18.32% | 11.68% |
D&A For EBITDA | 203.23 | 218.3 | 238.4 | 239.17 | 219.68 | 201.5 |
EBIT | 459.67 | 212.72 | 248.55 | 2,074 | 968.28 | 396.77 |
EBIT Margin | 8.13% | 3.92% | 4.89% | 24.84% | 14.93% | 7.75% |
Effective Tax Rate | 23.99% | 27.86% | 16.60% | 15.57% | 16.04% | 11.54% |
Revenue as Reported | 5,655 | 5,432 | 5,086 | 8,349 | 6,484 | 5,121 |
Advertising Expenses | - | 11.17 | 5.82 | 6.17 | 2.76 | 1.73 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.